Bicycle Therapeutics (BCYC)
| Bid | 8.85 |
| Market Cap | 609.12M |
| Revenue (ttm) | 35.28M |
| Net Income (ttm) | -169.08M |
| EPS (ttm) | -2.9 |
| PE Ratio (ttm) | -3.04 |
| Forward PE | -3.67 |
| Analyst | Buy |
| Ask | 10 |
| Volume | 208,278 |
| Avg. Volume (20D) | 323,762 |
| Open | 9.25 |
| Previous Close | 9.20 |
| Day's Range | 8.76 - 9.42 |
| 52-Week Range | 8.76 - 28.67 |
| Beta | 1.12 |
About BCYC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial ...
Analyst Forecast
According to 9 analyst ratings, the average rating for BCYC stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 217.46% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · businesswire.com
Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceCAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc...